Artificial Intelligence
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM
AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health and Windlas Biotech Pvt. Ltd. (Windlas), a leading Indian pharmaceutical contract drug development and manufacturing organization, announced today the launch in India of PulmoHeal™ a first-of-its-kind integrated, consumer-centric solution for respiratory wellness.
The combined drug + AI telemedicine 360o care solution is designed to support the estimated 100 million people in India who suffer from respiratory problems and address the underlying challenges of a lack of cost-effective and lab-free methods for early diagnosis of diseases.
PulmoHeal™ consists of three components:
- the drug PulmoHeal™, a broad-spectrum, lung therapy food supplement that is supported by a multi-centre rigorous clinical study that has demonstrated efficacy against a viral respiratory infection- COVId-19;
- a mobile app called ArtiHealth™ powered by Mateon’s AI supercomputing platform that allows patients to submit a questionnaire and a daily cough recording to receive real-time information on their respiratory function and progress over time; and
- a post-marketing survey (PMS) platform to crowd-source user experience for new indications.
- Additional information at www.pulmoheal.com
Artemisinin – the active component in PulmoHeal™– is derived from the extract of the indigenous plant Artemisia, which has exhibited multiple pharmacological activity against inflammation, viral infections, and lung repair.
Online channels include Amazon, Flipkart and 1mg.com, PulmoHeal™ can be taken periodically by those affected by respiratory viral infection, asthma, hay fever, or smokers and even those living in smog infested cities to improve their lung health and breathing functions. Additional information at www.pulmoheal.com
Mr Hitesh Windlass, MD, Windlas Biotech, commented, “Windlas, with its US partner Mateon, is the first company in the world to bring forward an integrated consumer-centric solution to respiratory health. PulmoHeal™ is a unique combination of cutting-edge manufacturing, clinical drug development, and AI, which harnesses the power of traditional and modern science. The ARTIHealth™ model can be replicated for a range of therapies, including monitoring COVID-19 infection. Our work with Mateon on PulmoHeal™ has been accepted by leading peer-reviewed journals in modern medicine and we shall continue to build on our momentum in bringing 360o solution to all facets of healthcare.”
Saran Saund, CBO and GM of AI Division, Mateon, commented, “To date, standard of care for mild and moderate COVID-19 patients is primarily limited to self-quarantine due to a significant strain of medical resources, without any drug therapy. Such patients can benefit from PulmoHeal™. We are optimistic that our solution will be beneficial even beyond current pandemic by empowering the patients and reducing burden on health care providers”.
Dr Vuong Trieu, CEO and Chairman of Mateon said, “We are pleased to be able to leverage on the deep tradition of Indian medicine and advanced artificial intelligence and supercomputing technologies under one umbrella to create this innovative solution to healthcare, one which we hope to replicate throughout the world across multiple indications.” Dr. Trieu added, “With our continued drive to remove inefficiencies from drug development and clinical trial processes, this platform sets the stage for continual improvement of drug development and clinical trials by democratizing the drug development process through patient-driven research.”
About PulmoHeal™: Clinical data suggests that PulmoHeal™ efficacy is statistically significant and more than doubles the recovery rate of COVID-19 patients. These results have been published in a prestigious peer reviewed international journal Frontiers in Pharmacology and Clinical Pharmacology. More information available at www.pulmoheal.com.
About AI Telemedicine platform: Mateon’s AI telemedicine platform combines a mobile app called ArtiHealth™ for consumers to self-monitor their respiratory health using AI-driven logic. It also enables a post-marketing survey to allow crowd sourcing of data from patients to provide large scale real world clinical data necessary for a evaluation of PulmoHeal™ in respiratory diseases such as COPD and asthma. A QR code on the product package allows consumers to download the app on their mobile device. For additional information, please visit: www.pulmoheal.com.
About Windlas Biotech Pvt. Ltd, India: Windlas is a 20-year-old company with a strong track record of research, development, manufacturing, and distribution of pharmaceutical products in India, USA and several other emerging markets. It has four large scale manufacturing facilities employing more than 1500 employees and is the 5th largest Contract Development and Manufacturing Organization (CDMO) serving top innovator as well as generic pharma companies across the world. It has developed more than 500 different formulations (> 2Billion doses annually) of anti-viral, cardiovascular, anti-diabetic, anti-infective, CNS and dermatology products. For more information, please visit https://windlas.com/
About Mateon Therapeutics: Mateon was created by the 2019 merger with Oncotelic, which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare paediatric cancers. Mateon has rare paediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.mateon.com.
Mateon’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe”, “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.
Contact Information:
For Mateon Therapeutics, Inc.:
Amit Shah
[email protected]
******
Artificial Intelligence
Automotive Digital Cockpit Domain Controller Power Expected to Double by 2030
NEW YORK, March 28, 2024 /PRNewswire/ — The lengthening lifecycle of vehicles is driving automotive Original Equipment Manufacturers (OEMs) to plan several years of customer support through regular Over-the-Air (OTA) updates. Achieving this requires a digital Cockpit Domain Controller (CDC) with an architecture that supports long-term updating and maintenance. According to a new report from global technology intelligence firm ABI Research, the computing power of the CDC will increase significantly over the next few years, with graphical computing power and deep-learning processing power (for AI-powered functions) expected to double by 2030 for an average mid-market CDC.
OEMs are beginning to plan for several years of support, both in software patches and bug fixes, and for delivering new added value features to the driving experience. “This support and feature roadmap requires a hardware and software architecture that supports the continuous updating of vehicles over time. OEMs need a system that accommodates quick, targeted updates by shipping vehicles with planned overhead in computing power, software containerization, and robust hypervisors. These can be accommodated by silicon vendors such as NVIDIA or Qualcomm with their suite of high-powered System-on-Chips (SoCs), along with hypervisor and software specialists such as Blackberry QNX. The ecosystem hasn’t fully adjusted to OTA updates in mixed-criticality systems like the digital cockpit domain controller yet, with most OEMs speculating about the level of computing power that is needed for several years of support and few going to their silicon and tier-one partners with roadmaps of planned features,” explains Abu Miah, Smart Mobility and Automotive Analyst at ABI Research.
The computing power of the CDC will increase significantly over time. The Tera Floating-Point Operations per Second (TFLOPS) of an average mid-market CDC is expected to rise from 1 TFLOPS in 2023 to 2.5 TFLOPS by 2030. Miah adds, “One of the primary drivers of this increase is the implementation of a larger number of higher resolution screens in the vehicle to accommodate new high-end gaming and video-on-demand features.”
Building a ‘future-proofed’ CDC is not as simple as throwing compute power at the vehicle. “OEMs, tier ones, and silicon vendors must all work toward an ecosystem of hardware and software agnosticism, modular architecture, and collaborative software development if they are to match customers’ expectations of updates, patches, and bug fixes from the consumer electronics space,” Miah concludes.
These findings are from ABI Research’s Future-Proofing Digital Cockpit Domain Controllers application analysis report. This report is part of the company’s Smart Mobility and Automotive research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Application Analysis reports present an in-depth analysis of key market trends and factors for a specific technology.
About ABI Research
ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.
ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
Contact Info:
GlobalDeborah Petrara Tel: +1.516.624.2558 [email protected]
Logo – https://mma.prnewswire.com/media/2309035/ABI_Research_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/automotive-digital-cockpit-domain-controller-power-expected-to-double-by-2030-302101973.html
Artificial Intelligence
ACL Digital in Collaboration with AWS and Infineon to Participate at Embedded World 2024
SAN JOSE, Calif., March 28, 2024 /PRNewswire/ — ACL Digital, an ALTEN group company, is a pioneer in design-led digital experience, innovation, enterprise IT modernization, and product engineering services, announced that ACL Digital, in collaboration with AWS and Infineon, is going to showcase its AWS IoT & Cloud capabilities at Embedded World 2024, Hall 4 (Booth #4-552) from April 9 to April 11 in Nuremberg, Germany.
ACL Digital, a top-tier AWS Services partner, propels organizations of all sizes to navigate digital transformation to accelerate time-to-market. The company provides comprehensive support, from adopting to modernizing IT infrastructure on AWS. By leveraging expertise in architecture, security, migration, and operations, ACL Digital unlocks the full potential of AWS, streamlining IoT and cloud journeys and fast-tracking business growth and innovation.
The AWS Advanced Tier partnership enables ACL Digital to leverage AWS expertise, its robust support ecosystem and best practices to deliver customer delight.
ACL Digital offers visitors at Embedded World 2024 a chance to experience the exclusive demo of a Smart Stove Solution, built by leveraging the AWS Cloud and Infineon platform and how it has added value to our customers.
With over 100 AWS-certified experts, ACL Digital empowers clients to achieve breakthrough results in their digital transformation. Also, the leading digital transformation company supports global clients in navigating the complexities of cloud implementation, migration and digital transformation with ease and helping them unlock new growth opportunities.
About AWS
Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 105 Availability Zones within 33 geographic regions, with announced plans for 12 more Availability Zones and four more AWS Regions in Malaysia, New Zealand, Thailand, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit https://aws.amazon.com .
About Infineon
Infineon Technologies AG is a global semiconductor leader in power systems and IoT. Infineon drives decarbonization and digitalization with its products and solutions. The company has around 58,600 employees worldwide and generated revenue of about €16.3 billion in the 2023 fiscal year (ending 30 September). Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the OTCQX International over-the-counter market (ticker symbol: IFNNY). To learn more about Infineon, visit https://www.infineon.com/
About ACL Digital
ACL Digital an ALTEN Group Company, is a digital product innovation and engineering leader. We help our clients design and build innovative products (AI, Cloud, and Mobile ready), content and commerce-driven platforms, and connected, converged digital experiences for the modern world through a design-led Digital Transformation framework.
Headquartered in Silicon Valley, ACL Digital is a leader in design-led digital experience, innovation, enterprise modernization, and product engineering services converging to Technology, Media & Telecom. The company has a workforce of 57,000+ spread across more than 30+ countries.
View original content:https://www.prnewswire.co.uk/news-releases/acl-digital-in-collaboration-with-aws-and-infineon-to-participate-at-embedded-world-2024-302101481.html
Artificial Intelligence
Gilbarco Veeder-Root champions fuel efficiency, clean fuels and diesel rebate solutions in mining
JOHANNESBURG, March 28, 2024 /PRNewswire/ — Global leader in technology solutions OEM Gilbarco Veeder-Root (GVR) is dedicated to enhancing operational performance by delivering comprehensive end-to-end wetstock, industrial, mining, and business-to-business solutions, all tailored to meet the specific needs of the customer.
By encompassing every aspect of mining operations, GVR commercial and industrial Middle East and Africa director Westtar Kapito says, “the company is setting new benchmarks for fuel efficiency, safety and sustainability within the mining industry”.
As part of a holistic approach to mining excellence, Kapito explains that Gilbarco’s integrated fuel and fleet management technology solutions are designed to address the multifaceted challenges of the mining industry.
Some of these facets include wetstock control, equipment maintenance and management, fleet management and automation, compliance monitoring and environmental sustainability, as well as driving productivity and profitability through innovation.
In addition, the introduction of Gilbarco’s clean fuel solution exemplifies the company’s commitment to maintaining equipment integrity and performance.
This technology, GVR says, monitors in real-time the status of up to 16 “clean fuels” key performance matrices, thereby ensuring that dirty fuel is flagged and not transferred into mining equipment which would affect engines and injectors and thus lower productivity.
Gilbarco’s comprehensive site automation solutions empower mining companies with critical data analytic insights, facilitating efficient monitoring and management of fleet and fuel inventory. Gilbarco’s dataFLEX360 platform plays a pivotal role, offering near real-time reporting and analytics to drive informed decision-making and operational agility.
dataFLEX360 is a Web-based, cloud-hosted strategic operational insights platform. The system ensures accurate, reliable and relevant reporting of all fuel, fleet and asset transactions, and provides for proactive corrective measures to reduce complex reporting and gives a consolidated and comprehensive view across all sites and assets.
With reconciliations at its core, dataFLEX360 provides solution accuracy on operational data.
Integral to the company’s solutions is compliance with Global Industry Standards and environmental stewardship, from leak detection to vapour recovery and clean fuel technologies. Gilbarco’s products are designed to ensure compliance and minimise the carbon footprint of mining operations.
Additionally, through the company’s innovative telematics technology and the data generated, it can systematically and seamlessly generate South African Revenue Services- (SARS-) compliant fuel rebate reports for any selected tax period.
GVR’s technology provides a full audit trail required for eligibility for SARS rebates, and its reporting platform simplifies logbook and data gathering required, enabling successful rebate claims and return on investment.
Photo – https://mma.prnewswire.com/media/2373644/Gilbarco_Veeder_Roots_MEA.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gilbarco-veeder-root-champions-fuel-efficiency-clean-fuels-and-diesel-rebate-solutions-in-mining-302102415.html
-
Artificial Intelligence7 days ago
Merkle Launches Global Messaging Solution
-
Artificial Intelligence6 days ago
Document Collaboration Hub (DCH) by Netcare International Now Available on Microsoft AppSource
-
Artificial Intelligence6 days ago
Smartkem Commences Project with RiTdisplay To Develop World’s First Commercially Ready Active-Matrix OLED Display Using OTFT Technology
-
Artificial Intelligence6 days ago
Hexaware Dominates Whitelane Research 2024 BeLux IT Sourcing Study: A Triumph in Continued CSAT Excellence
-
Artificial Intelligence6 days ago
Wine of Moldova offers a glimpse of the future with its game-changing AI tool
-
Artificial Intelligence7 days ago
Volvo Cars taps TDCX to enhance customer experience for Europe
-
Artificial Intelligence6 days ago
World System Integrator Conference (WSIC) 2024 A Showcase of New Initiatives
-
Artificial Intelligence7 days ago
Globant Presents “Taste ID”: the New Ad by GUT Pokes Fun at Legacy Tech Industry